drugset / Trial / NCT06687070
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Non-randomizedSequentialOpen-labelTreatment
Summary
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Timeline
- Start
- 2024-12-17
- Primary completion
- 2026-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2449 | Small molecule | — | Oral |
| Subject | PLD | Unknown | — | Other |